Tolerability, efficacy and retention rate of Brivaracetam in patients previously treated with Levetiracetam: A monocenter retrospective outcome analysis
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
PURPOSE To determine the potential for improvement of tolerability and efficacy by the use of Brivaracetam (BRV) in patients previously treated with Levetiracetam (LEV). METHODS We retrospectively analyzed data from patients treated with BRV at the Freiburg Epilepsy Center. RESULTS 102 patients with a minimum follow up of 6 months were included. The mean duration of treatment was 301.6 (± 156.8) days. 60 patients underwent an overnight switch from LEV to BRV, 42 patients have had LEV at some time in the past. Out of 46 patients with a quantifiable seizure baseline and follow-up of 6 months 10 patients (21.7%) had an increase in seizure frequency, 15 (32.6%) were 50%-responders, and 10 patients (21.7%) became newly seizure-free. Patients with an overnight switch from LEV to BRV who had a reduction in seizure frequency had the highest dose ratio of the final BRV dose to LEV (1:10.1) and the biggest difference between the starting and final dose of BRV, suggesting that previously seizure control was limited by the tolerated LEV dosage. The retention rate after 6 months was 80.4%. 28 out of 49 (57.1%) patients directly switched from LEV to BRV because of psychiatric side effects reported an improved tolerability. 10 out of 42 (23.8%) patients not directly switched but with a history of LEV use had predominantly psychiatric side effects during BRV treatment. CONCLUSION Overall, intolerability or ineffectiveness of prior treatment with LEV seems not to preclude a good response to BRV. BRV was substantially better tolerated than LEV.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Early Identification of Refractory Epilepsy
Kwan, P., & Brodie, M. J. (2000) · New England Journal of Medicine · doi:10.1056/nejm200002033420503 · Cited by 5,204
Klitgaard, H., Matagne, A., Nicolas, J., Gillard, M., Lamberty, Y., De Ryck, M., Kaminski, R. M., Leclercq, K., Niespodziany, I., Wolff, C., et al. (2016) · Epilepsia · doi:10.1111/epi.13340 · Cited by 168
Cited by
Levetiracetam and brivaracetam: A review of evidence from clinical trials and clinical experience
Steinhoff, B. J., & Staack, A. M. (2019) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286419873518 · Cited by 99
Fukuyama, K., & Okada, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094473 · Cited by 22
Presynaptic antiseizure medications-basic mechanisms and clues for their rational combinations
Czapińska-Ciepiela, E. K., Łuszczki, J., Czapiński, P., Czuczwar, S. J., & Lasoń, W. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00603-7 · Cited by 13
“The optimal scheme in which the drugs should be replaced is not clear; however, the most frequently used ratio is 10:1 (for example, 1000 mg of levetiracetam is the equivalent of 100 mg of brivaracetam) or 15:1 [103, 106].”
Background
Metadata
- Authors
- Hirsch, M., Hintz, M., Specht, A., & Schulze-Bonhage, A.
- Venue
- Seizure
- Publisher
- Elsevier BV
- Published
- 2018-10
- Volume
- 61
- Pages
- 98-103
- ISSN
- 1059-1311 (ISSN-L)
- OpenAlex
- W2883620991
- Cited by
- 82
- References
- 2
- FWCI
- 5.03
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tolerability, efficacy and retention rate of Brivaracetam in patients previously treated with Levetiracetam: A monocenter retrospective outcome analysis. https://app.cochat.ai/papers/10.1016/j.seizure.2018.07.017
- The paper
- Hirsch, M., Hintz, M., Specht, A., & Schulze-Bonhage, A. (2018). Tolerability, efficacy and retention rate of Brivaracetam in patients previously treated with Levetiracetam: A monocenter retrospective outcome analysis. Seizure. https://doi.org/10.1016/j.seizure.2018.07.017
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.